Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,540,000 shares, a decrease of 10.5% from the September 15th total of 1,720,000 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average trading volume of 200,200 shares, the days-to-cover ratio is presently 7.7 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.00.
View Our Latest Report on Kodiak Sciences
Institutional Trading of Kodiak Sciences
Kodiak Sciences Stock Up 4.2 %
Shares of KOD opened at $3.00 on Thursday. Kodiak Sciences has a 52-week low of $1.37 and a 52-week high of $7.77. The stock has a market cap of $157.61 million, a PE ratio of -0.68 and a beta of 2.34. The firm’s fifty day moving average is $2.61 and its two-hundred day moving average is $2.98.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. As a group, research analysts anticipate that Kodiak Sciences will post -3.52 earnings per share for the current year.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
- Five stocks we like better than Kodiak Sciences
- What is Put Option Volume?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How Can Investors Benefit From After-Hours Trading
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Financial Services Stocks Investing
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.